美国宾夕法尼亚大学化学系：Madeleine M. Joullie教授的研究小组 (合成有机化学)
synthetic organic chemistry including heterocyclic and medicinal chemistry
Dr. Madeleine M. Joullie - Class of 1970 Professor of Chemistry
Madeleine M. Joullie
PHONE: (215) 898-3158
EDUCATION AND ACADEMIC HISTORY:
B.Sc. Simmons College (1949)
M.Sc.; University of Pennsylvania (1950)
Ph.D. University of Pennsylvania (1953)
ACS Philadelphia Section Award (1972)
ACS Garvan Medal (1978)
American Cyanamid, Faculty Award (1984)
American Institute of Chemists, Scroll Award (1985)
member of Sigma Xi, Sigma Delta Epsilon
member of ACS
Philadelphia Organic Chemist's Club Award (1994)
ACS Henry Hill Award (1994)
Arthur C. Cope Senior Scholar Awards (2002)
Fellow of the New York Academy of Science
Co-author of two books and several chapters
Current efforts are in the following areas: (1) synthesis and chemistry of five-membered heterocycles and natural products containing such units; (2) synthesis and chemistry of fungal metabolites; (3) synthesis and chemistry of cyclopeptide alkaloids; (4) synthesis of biologically important depsipeptides; (5) synthesis of novel ninhydrins; (6) synthesis of anti- angiogenic agents.
1. Utilization of D-ribonolactone and other sugars as precursors in the synthesis of several structurally challenging molecules is currently underway in their laboratory.
2. The synthesis of naturally occurring fungal metabolites containing a common hexasubstituted aromatic ring but different side chains such as colletochlorin D, ascofuranone and ascochlorin are another area of interest. The biological activities of those natural products range from high hypolipidemic action to anticancer and antiprotozoan activity.
3. Cyclopeptide alkaloids are natural products found in many plant families. A broad program aimed at developing methodology for the synthesis of the most commonly found thirteen- and fourteen-membered ring cyclopeptide alkaloids is currently underway. Sanjoin, used in Chinese folk medicine is one of their targets. Other antitumor cyclic peptides provenient from plants, the astins, are also under investigation.
4. Didemnins are a new class of depsipeptides isolated from a Carribean tunicate of the family Didemnidae, a species of the genus Trididemnum. These cyclic peptides have shown highly active antiviral and antitumor agents. The synthetic studies carried out in their laboratory have produced synthetic and spectral evidence for the absolute configuration of the asymmetric centers of the hydroxyisovalerylpropionyl (HIP) unit of the macrocycle, thereby requiring a revision of the original stereochemistry. The stereocontrolled total synthesis of these natural products has already been accomplished. The synthesis of several beta-turn mimics and constrained analogs are under investigation. Because of a broad program to develop efficient synthetic routes to the didemnins, other cyclodepsipeptides have been chosen as the next targets. The choice of these compounds was not only based on their relationship to didemnins but also on previous synthetic studies of products originating from polyketide
biosynthesis, and earlier investigations of carbohydrates.
5. Novel ninhydrins are being synthesized as reagents for the detection of amino acids.
6. They have found that sulfated beta-cyclodextrin mimicked heparin advantageously. This effective synthetic product is of utmost importance in the control of angiogenesis and has other important applications in medicine. This recent discovery uncovers a new class of anti-angiogenic agents, consisting of a hydrophilic carrier and a hydrophobic angiostat, and offers a unique opportunity for the development of chemical technologies which will have important applications in the bio- and medical sciences. They are therefore continuing these studies with several goals in mind. They are investigating new and more effective carriers, they are designing single species that contain both the angiostat and carrier, and they are looking for new and more effective angiostats.
2002年美国化学会国家奖获得者 (ACS 2002 National Award Recipients)
Summary by 杨宏伟 on 2003-12-09
Last updated by 杨宏伟 on 2003-12-09